Ledasorexton

Ledasorexton (INNTooltip International Nonproprietary Name; developmental code name E-2086) is a selective orexin OX₂ receptor agonist which is under development for the treatment of narcolepsy.^[1][2] It is taken orally.^[1] The drug is under development by Eisai.^[1][2] As of May 2026, it is in phase 2 clinical trials for narcolepsy.^[1][2]

Other namesE-2086; E2086

Routes of
administrationOral^[1]

Drug classOrexin OX₂ receptor agonist; Wakefulness-promoting agent

CAS Number

• 2758363-88-9

Quick facts Clinical data, Other names ...

Ledasorexton

Clinical data
Other names	E-2086; E2086
Routes of administration	Oral[1]
Drug class	Orexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
IUPAC name (2R)-2-cyclopropyl-2-[(1S,5R)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]acetamide
CAS Number	2758363-88-9
PubChem CID	162702128
ChemSpider	133324961
UNII	YF7U7E62EL
ChEMBL	ChEMBL5795221
Chemical and physical data
Formula	C22H32FN5O2
Molar mass	417.529 g·mol−1
3D model (JSmol)	Interactive image
SMILES CO[C@@H]1CN(CC[C@@H]1C2C[C@H]3CC[C@@H](C2)N3[C@H](C4CC4)C(=O)N)C5=NC=C(C=N5)F
InChI InChI=1S/C22H32FN5O2/c1-30-19-12-27(22-25-10-15(23)11-26-22)7-6-18(19)14-8-16-4-5-17(9-14)28(16)20(21(24)29)13-2-3-13/h10-11,13-14,16-20H,2-9,12H2,1H3,(H2,24,29)/t14?,16-,17+,18-,19-,20-/m1/s1 Key:AXOUSJFGEOVDQT-GFVFYWETSA-N

Close